(Z)-((((2-(dimethylamino)ethyl)thio)carbonyl)azanediyl)bis(ethane-2,1-diyl) dioleate | 1415981-73-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (Z)-((((2-(dimethylamino)ethyl)thio)carbonyl)azanediyl)bis(ethane-2,1-diyl) dioleate
• 英文别名: 2-[2-(dimethylamino)ethylsulfanylcarbonyl-[2-[(Z)-octadec-9-enoyl]oxyethyl]amino]ethyl (Z)-octadec-9-enoate
• CAS: 1415981-73-5
• 化学式: C₄₅H₈₄N₂O₅S
• 分子量: 765.238
• InChiKey: UWZHXGIUVWJFNJ-WRBBJXAJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  15.4
• 重原子数：
  53
• 可旋转键数：
  42
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.84
• 拓扑面积：
  101
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  (Z)-((((2-(dimethylamino)ethyl)thio)carbonyl)azanediyl)bis(ethane-2,1-diyl) dioleate 、 2-溴乙醇 生成 2-((bis(2-(oleoyloxy)ethyl)carbamoyl)thio)-N-(2-hydroxyethyl)-N,N-dimethylethan-aminium bromide
  参考文献：
  名称：

  [EN] COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING SIRNA ACTIVITY
  [FR] COMPOSÉS POUR L'ADMINISTRATION DE MÉDICAMENT CIBLÉE ET L'AUGMENTATION DE L'ACTIVITÉ ARNSI

  摘要：

  公开号：

  WO2012170952A9
• 作为产物：
  描述：

  tert-butyl N,N-bis(2-((Z)-octadec-9-enoyloxy)ethyl)carbamate 在 三氟乙酸 、 氯甲酸三氯甲酯 作用下， 以 二氯甲烷 为溶剂， 反应 0.33h， 生成 (Z)-((((2-(dimethylamino)ethyl)thio)carbonyl)azanediyl)bis(ethane-2,1-diyl) dioleate
  参考文献：
  名称：

  LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS

  摘要：

  该描述针对可用于增强脂质体中治疗剂传递的可电离脂质。

  公开号：

  US20130330401A1

文献信息

• CATIONIC LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS
  申请人：Niitsu Yoshiro

  公开号：US20130022665A1

  公开（公告）日：2013-01-24

  Here described are compounds of formula I: wherein R 1 and R 2 is independently selected from a group consisting of C 10 to C 18 alkyl, C 12 to C 18 alkenyl, and oleyl group; wherein R 3 and R 4 are independently selected from a group consisting of C 1 to C 6 alkyl, and C 2 to C 6 alkanol; wherein X is selected from a group consisting of —CH 2 —, —S—, and —O— or absent; wherein Y is selected from —(CH 2 ) n —S(CH 2 ) n , —O(CH 2 ) n —, thiophene, —SO 2 (CH 2 ) n —, and ester, wherein n=1-4; wherein a=1-4; wherein b=1-4; wherein c=1-4; and wherein Z is a counterion; as well as compositions and pharmaceutical formulations including compounds of formula I which are useful for the delivery of therapeutic agents; and methods of using these compositions and formulations.

  本文描述了式I的化合物：其中R1和R2分别选自由C10到C18烷基，C12到C18烯基和油酰基组成的一组；其中R3和R4分别选自由C1到C6烷基和C2到C6烷醇组成的一组；其中X选自由—CH2—，—S—和—O—或不存在的一组；其中Y选自由—（CH2）n—S（CH2）n，—O（CH2）n—，噻吩，—SO2（CH2）n—和酯的一组，其中n=1-4；其中a=1-4；其中b=1-4；其中c=1-4；其中Z是一个带电离子；以及包括式I化合物的组合物和药物制剂，用于传递治疗剂；以及使用这些组合物和制剂的方法。
• Lipids for Therapeutic Agent Delivery Formulations
  申请人：Nitto Denko Corporation

  公开号：US20160074514A1

  公开（公告）日：2016-03-17

  The description is directed to ionizable lipids useful for enhancing the delivery of therapeutic agents in liposomes.

  本文描述了可离子化脂质，用于增强脂质体中治疗剂的传递。
• Cationic Lipids for Therapeutic Agent Delivery Formulations
  申请人：Nitto Denko Corporation

  公开号：US20160137593A1

  公开（公告）日：2016-05-19

  Here described are compounds of formula I: wherein R 1 and R 2 are independently selected from C 10 to C 18 alkyl, C 12 to C 18 alkenyl, and oleoyl; R 3 and R 4 are independently selected from C 1 to C 6 alkyl and C 2 to C 6 alkanol; X is selected from —CH 2 —, —S—, and —O—, or X is absent; Y is selected from —(CH 2 ) n , —S(CH 2 ) n —, —O(CH 2 ) n —, -thiophene-, —SO 2 (CH 2 ) n —, and ester; n=1-4; a=1-4; b=1-4; c=1-4; and Z − is a counterion. Also described herein are compositions and pharmaceutical formulations including compounds of formula I which are useful for the delivery of therapeutic agents, and methods of using these compositions and formulations.

  本文描述了公式I的化合物：其中R1和R2独立选择自C10到C18烷基，C12到C18烯基和油酰基; R3和R4独立选择自C1到C6烷基和C2到C6醇基; X从—CH2—，—S—和—O—中选择，或X不存在; Y从—(CH2)n，—S(CH2)n—，—O(CH2)n—，-噻吩-，—SO2(CH2)n—和酯中选择; n=1-4; a=1-4; b=1-4; c=1-4; Z-是计数离子。本文还描述了包括公式I化合物的组合物和制药配方，这些化合物对于输送治疗剂是有用的，以及使用这些组合物和配方的方法。
• TARGETING MOLECULE AND UTILIZATION THEREOF
  申请人：Nitto Denko Corporation

  公开号：EP3127915A1

  公开（公告）日：2017-02-08

  Provided are: a targeting molecule targeting a target cell which is selected from the group consisting of a stellate cell, a myofibroblast, a cancer-associated fibroblast, a tumor cell and a cell expressing STRA6, said targeting molecule being selected from the group consisting of (1) a peptide containing an amino acid sequence in the cell-binding region of RBP, (2) a variant peptide of the aforesaid peptide (1), said variant peptide having a comparable targetability to peptide (1), and (3) a peptide mimetic having a comparable targetability to peptide (1) or peptide (2); a targeting agent, a carrier, a complex and a medicinal composition each comprising the targeting molecule; a method for treating, examining, diagnosing or monitoring a disease related to the aforesaid target cell; a method for labeling, detecting or imaging the target cell, etc.

  提供了一种靶向分子，其靶向的靶细胞选自由星状细胞、肌成纤维细胞、癌相关成纤维细胞、肿瘤细胞和表达 STRA6 的细胞组成的组，所述靶向分子选自由以下组成的组 (1) 含有 RBP 细胞结合区氨基酸序列的多肽、(2) 上述多肽（1）的变体多肽，所述变体多肽具有与多肽（1）相当的靶向性；以及 (3) 具有与多肽（1）或多肽（2）相当的靶向性的多肽模拟物；一种靶向制剂、一种载体、一种复合物和一种药物组合物，每一种都包含靶向分子；一种治疗、检查、诊断或监测与上述靶细胞有关的疾病的方法；一种对靶细胞进行标记、检测或成像的方法等。
• SKIN FIBROSIS TREATMENT AGENT
  申请人：Nitto Denko Corporation

  公开号：EP3536343A1

  公开（公告）日：2019-09-11

  The present invention relates to: a carrier for delivering a retinoid-containing substance used by extracellular-matrix-producing cells in the skin; a skin fibrosis treatment agent using said carrier; a preparation kit for said treatment agent; a production method for said carrier; and a production method for said treatment agent.

  本发明涉及：一种用于输送皮肤细胞外基质生成细胞所使用的含维甲酸物质的载体；一种使用所述载体的皮肤纤维化治疗剂；一种用于所述治疗剂的制备试剂盒；一种用于所述载体的生产方法；以及一种用于所述治疗剂的生产方法。